BDC-1001
BBI-20201001
Phase 2 small_molecule terminated
Quick answer
BDC-1001 for HER2-positive Solid Tumors is a Phase 2 program (small_molecule) at Bolt Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bolt Biotherapeutics
- Indication
- HER2-positive Solid Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated